SignatureFD’s Akebia Therapeutics AKBA Stock Holding History

SignatureFD’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-811	Closed	-$2K	–	3127
2021 Q4	$2K	Sell	811 -1,392	-63%	-$3.8K	﹤0.01%	2663
2021 Q3	$6K	Buy	2,203 +678	+44%	+$1.94K	﹤0.01%	2269
2021 Q2	$6K	Buy	1,525 +1,102	+261%	+$3.71K	﹤0.01%	2176
2021 Q1	$1K	Hold	423	–	–	﹤0.01%	2580
2020 Q4	$1K	Buy	423 +29	+7%	+$85	﹤0.01%	2373
2020 Q3	$1K	Buy	+394	New	+$3.46K	﹤0.01%	2353

Other funds holding AKBA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

OCM

Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return

SignatureFD's AKBA Position: Q1 2022 in Review

SignatureFD sold out of Akebia Therapeutics (AKBA) in Q1 2022, closing a stake of 811 shares — an estimated $2K sold.

SignatureFD first reported a position in AKBA in Q3 2020 and held it in 6 quarters. The position peaked at $6K in Q3 2021. 124 funds tracked by Wall St. Rank hold AKBA as of Q1 2022.

SignatureFD reported no remaining Akebia Therapeutics position as of Q1 2022 after selling out during the quarter.
SignatureFD sold 811 Akebia Therapeutics shares in Q1 2022, an estimated $2K.
SignatureFD first reported a position in Akebia Therapeutics in Q3 2020 and held it in 6 quarters.
SignatureFD's Akebia Therapeutics position peaked at $6K in Q3 2021.
124 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2022.

Based on SignatureFD's 13F filing for Q1 2022, filed 2 May 2022.